| Literature DB >> 29317593 |
Turhan Canli1, Lei Yu2, Xiaoqing Yu3, Hongyu Zhao3, Debra Fleischman2, Robert S Wilson2, Philip L De Jager4, David A Bennett2.
Abstract
Subjective social isolation, loneliness, is associated with poor mental and physical health, but the underlying molecular mechanisms are poorly understood. Here we analyzed loneliness data collected on average 5 years ante-mortem and RNA gene expression at death in postmortem dorsolateral prefrontal cortex (DLPFC) from 181 participants in the Rush Memory and Aging Project (MAP), a longitudinal, prospective cohort study of common chronic conditions of aging. Our analytic protocol controlled for biographical variables (age, sex, education), psychological and health variables (depressive symptoms, interval between assessment and autopsy, slope of cognitive decline, AD pathology, presence of infarcts) and RNA integrity. Our results are based on a pre-ranked Gene Set Enrichment Analysis (GSEA) at FDR-corrected q-values <0.05, using these collections from the Molecular Signatures Database (v6.0 MSigDB): (1) Hallmarks, (2) Canonical, (3) Gene Ontology (GO), (4) Chemical and Genetic Perturbations, (5) Immunologic Signatures, (6) Oncogenic Signatures, and (7) Cancer Modules. We now report on 337 up-regulated and 43 down-regulated gene sets, among which the most significant ones were associated with Alzheimer's disease, psychiatric illness, immune dysfunction, and cancer. These gene sets constitute attractive targets for future studies into the molecular mechanisms by which loneliness exacerbates a wide range of neurodegenerative, psychiatric, and somatic illnesses.Entities:
Mesh:
Year: 2018 PMID: 29317593 PMCID: PMC5802527 DOI: 10.1038/s41398-017-0086-2
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Characteristics of the study subjects (N=181)
| Age at death in years (mean, SD) | 89.5, 6.2 |
| Female Sex ( | 119, 65.8% |
| Education (mean, SD) | 14.7, 2.7 |
| CES-D (median, IQR) | 1.0, 0-2.0 |
| Baseline loneliness (mean, SD) | 2.3, 0.7 |
| Last loneliness measure prior to death (mean, SD) | 2.5, 0.7 |
| Time interval between baseline loneliness to autopsy (mean, SD) | 4.9, 2.0 |
| RIN scores (mean, SD) | 7.1, 1.0 |
| Annual rate of cognitive decline (mean, SD) | −0.015, 0.091 |
| Burden of AD pathology | 0.65, 0.37 |
| Presence of chronic infarcts | 75, 41.4% |
SD Standard deviation, IQR Interquartile range
Top-25 up- and down-regulated gene sets, based on normalized Enrichment Score
| Collection | Upregulated Sets (sorted by positive NES) | SIZE | ES | NES | NOM p-val | FDR q-val | FWER p-val | RANK AT MAX | LEADING EDGE |
|---|---|---|---|---|---|---|---|---|---|
| ChemGenPerturb | BLALOCK_ALZHEIMERS_DISEASE_UP | 198 | 0.35 | 4.28 | 0.000 | 0.000 | 0.000 | 1535 | tags=87%, list=55%, signal=179% |
| CancerModules | MODULE_5 | 90 | 0.43 | 3.94 | 0.000 | 0.000 | 0.000 | 1067 | tags=76%, list=38%, signal=118% |
| ChemGenPerturb | MILI_PSEUDOPODIA_HAPTOTAXIS_DN | 98 | 0.38 | 3.60 | 0.000 | 0.000 | 0.000 | 1228 | tags=79%, list=44%, signal=135% |
| ChemGenPerturb | REN_ALVEOLAR_RHABDOMYOSARCOMA_DN | 65 | 0.43 | 3.55 | 0.000 | 0.000 | 0.000 | 1307 | tags=88%, list=47%, signal=161% |
| CancerModules | MODULE_23 | 89 | 0.37 | 3.55 | 0.000 | 0.000 | 0.000 | 874 | tags=63%, list=31%, signal=89% |
| CancerModules | MODULE_88 | 112 | 0.33 | 3.42 | 0.000 | 0.000 | 0.000 | 882 | tags=60%, list=31%, signal=84% |
| CancerModules | MODULE_60 | 79 | 0.39 | 3.38 | 0.000 | 0.000 | 0.000 | 1425 | tags=87%, list=51%, signal=173% |
| GO | GO_VASCULATURE_DEVELOPMENT | 86 | 0.37 | 3.33 | 0.000 | 0.000 | 0.000 | 1545 | tags=91%, list=55%, signal=196% |
| CancerModules | MODULE_55 | 108 | 0.33 | 3.29 | 0.000 | 0.000 | 0.000 | 882 | tags=59%, list=31%, signal=83% |
| CancerModules | MODULE_38 | 89 | 0.36 | 3.29 | 0.000 | 0.000 | 0.000 | 1029 | tags=67%, list=37%, signal=103% |
| CancerModules | MODULE_6 | 67 | 0.40 | 3.29 | 0.000 | 0.000 | 0.000 | 1096 | tags=75%, list=39%, signal=120% |
| CancerModules | MODULE_84 | 76 | 0.38 | 3.26 | 0.000 | 0.000 | 0.000 | 1029 | tags=70%, list=37%, signal=107% |
| ChemGenPerturb | LEE_BMP2_TARGETS_UP | 112 | 0.31 | 3.24 | 0.000 | 0.000 | 0.000 | 1116 | tags=67%, list=40%, signal=107% |
| CancerModules | MODULE_1 | 69 | 0.38 | 3.24 | 0.000 | 0.000 | 0.000 | 1102 | tags=74%, list=39%, signal=119% |
| GO | GO_CELL_SURFACE | 115 | 0.32 | 3.24 | 0.000 | 0.000 | 0.000 | 1008 | tags=63%, list=36%, signal=95% |
| ChemGenPerturb | CHEN_METABOLIC_SYNDROM_NETWORK | 172 | 0.27 | 3.14 | 0.000 | 0.000 | 0.000 | 871 | tags=52%, list=31%, signal=71% |
| GO | GO_BLOOD_VESSEL_MORPHOGENESIS | 64 | 0.39 | 3.12 | 0.000 | 0.000 | 0.000 | 1545 | tags=92%, list=55%, signal=201% |
| GO | GO_IMMUNE_RESPONSE | 90 | 0.34 | 3.11 | 0.000 | 0.000 | 0.000 | 1469 | tags=84%, list=52%, signal=172% |
| Immunogenic | GSE21360_NAIVE_VS_PRIMARY_MEMORY_CD8_TCELL_UP | 28 | 0.54 | 3.10 | 0.000 | 0.001 | 0.001 | 1230 | tags=96%, list=44%, signal=170% |
| ChemGenPerturb | LEI_MYB_TARGETS | 44 | 0.44 | 3.09 | 0.000 | 0.000 | 0.000 | 1212 | tags=84%, list=43%, signal=146% |
| ChemGenPerturb | BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP | 56 | 0.41 | 3.08 | 0.000 | 0.000 | 0.000 | 845 | tags=64%, list=30%, signal=90% |
| GO | GO_CIRCULATORY_SYSTEM_DEVELOPMENT | 130 | 0.29 | 3.05 | 0.000 | 0.000 | 0.000 | 1137 | tags=65%, list=41%, signal=104% |
| GO | GO_EXTRACELLULAR_STRUCTURE_ORGANIZATION | 45 | 0.44 | 3.05 | 0.000 | 0.000 | 0.000 | 1025 | tags=78%, list=37%, signal=121% |
| ChemGenPerturb | MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3 | 155 | 0.27 | 3.04 | 0.000 | 0.000 | 0.000 | 1058 | tags=59%, list=38%, signal=90% |
| ChemGenPerturb | JOHNSTONE_PARVB_TARGETS_3_UP | 60 | 0.39 | 3.03 | 0.000 | 0.000 | 0.000 | 1081 | tags=73%, list=39%, signal=117% |
| Collection | Downregulated Sets (sorted by negative NES) | SIZE | ES | NES | NOM p-val | FDR q-val | FWER p-val | RANK AT MAX | LEADING EDGE |
| ChemGenPerturb | BLALOCK_ALZHEIMERS_DISEASE_DN | 158 | −0.46 | −5.89 | 0.000 | 0.000 | 0.000 | 1205 | tags=87%, list=43%, signal=144% |
| ChemGenPerturb | KIM_ALL_DISORDERS_CALB1_CORR_UP | 73 | −0.54 | −5.00 | 0.000 | 0.000 | 0.000 | 1248 | tags=97%, list=45%, signal=171% |
| ChemGenPerturb | MILI_PSEUDOPODIA_HAPTOTAXIS_UP | 48 | −0.43 | −3.30 | 0.000 | 0.000 | 0.000 | 1163 | tags=83%, list=42%, signal=140% |
| ChemGenPerturb | SHEN_SMARCA2_TARGETS_UP | 28 | −0.53 | −3.28 | 0.000 | 0.000 | 0.000 | 1243 | tags=96%, list=44%, signal=172% |
| GO | GO_SYNAPSE_PART | 101 | −0.29 | −3.11 | 0.000 | 0.000 | 0.000 | 1246 | tags=73%, list=44%, signal=127% |
| ChemGenPerturb | SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM | 19 | −0.60 | −3.11 | 0.000 | 0.000 | 0.002 | 1120 | tags=100%, list=40%, signal=165% |
| ChemGenPerturb | HAMAI_APOPTOSIS_VIA_TRAIL_UP | 52 | −0.38 | −3.10 | 0.000 | 0.000 | 0.002 | 1285 | tags=83%, list=46%, signal=150% |
| Oncogenic | KRAS.KIDNEY_UP.V1_UP | 27 | −0.50 | −3.06 | 0.000 | 0.000 | 0.000 | 1199 | tags=93%, list=43%, signal=160% |
| ChemGenPerturb | LU_AGING_BRAIN_DN | 25 | −0.53 | −3.04 | 0.000 | 0.000 | 0.002 | 1231 | tags=96%, list=44%, signal=170% |
| GO | GO_SYNAPSE | 117 | −0.27 | −3.04 | 0.000 | 0.000 | 0.000 | 1246 | tags=71%, list=44%, signal=122% |
| Oncogenic | CAHOY_NEURONAL | 18 | −0.60 | −3.02 | 0.000 | 0.000 | 0.000 | 995 | tags=94%, list=36%, signal=146% |
| ChemGenPerturb | SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_U | P 37 | −0.43 | −2.99 | 0.000 | 0.000 | 0.002 | 1160 | tags=84%, list=41%, signal=141% |
| ChemGenPerturb | VERHAAK_GLIOBLASTOMA_PRONEURAL | 29 | −0.46 | −2.79 | 0.000 | 0.001 | 0.009 | 1170 | tags=86%, list=42%, signal=147% |
| ChemGenPerturb | STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN | 48 | −0.36 | −2.78 | 0.000 | 0.001 | 0.009 | 1175 | tags=77%, list=42%, signal=131% |
| GO | GO_SYNAPTIC_SIGNALING | 64 | −0.32 | −2.78 | 0.000 | 0.001 | 0.006 | 1246 | tags=77%, list=44%, signal=135% |
| ChemGenPerturb | MIKKELSEN_MEF_ICP_WITH_H3K4ME3_AND_H3K27ME3 | 10 | −0.74 | −2.78 | 0.000 | 0.001 | 0.010 | 737 | tags=100%, list=26%, signal=135% |
| Oncogenic | PRC2_EED_UP.V1_UP | 21 | −0.53 | −2.76 | 0.000 | 0.000 | 0.002 | 494 | tags=67%, list=18%, signal=80% |
| Immunogenic | GSE34156_NOD2_LIGAND_VS_TLR1_TLR2_LIGAND_24H_TRE | T 13 | −0.63 | −2.75 | 0.000 | 0.025 | 0.037 | 878 | tags=92%, list=31%, signal=134% |
| GO | GO_CATION_CHANNEL_COMPLEX | 29 | −0.45 | −2.75 | 0.000 | 0.001 | 0.008 | 1226 | tags=90%, list=44%, signal=158% |
| GO | GO_MICROTUBULE | 31 | −0.41 | −2.69 | 0.000 | 0.002 | 0.014 | 512 | tags=55%, list=18%, signal=66% |
| GO | GO_MRNA_METABOLIC_PROCESS | 36 | −0.40 | −2.67 | 0.000 | 0.002 | 0.019 | 1157 | tags=81%, list=41%, signal=135% |
| ChemGenPerturb | WEI_MYCN_TARGETS_WITH_E_BOX | 65 | −0.30 | −2.65 | 0.000 | 0.001 | 0.021 | 1163 | tags=71%, list=42%, signal=118% |
| GO | GO_BEHAVIOR | 70 | −0.29 | −2.65 | 0.000 | 0.002 | 0.022 | 1248 | tags=73%, list=45%, signal=128% |
| GO | GO_RNA_PROCESSING | 48 | −0.34 | −2.62 | 0.000 | 0.003 | 0.032 | 1180 | tags=75%, list=42%, signal=127% |
| ChemGenPerturb | GEORGES_TARGETS_OF_MIR192_AND_MIR215 | 87 | −0.25 | −2.59 | 0.000 | 0.002 | 0.037 | 1438 | tags=77%, list=51%, signal=153% |
SIZE Number of genes in the gene set after filtering out those genes not in the expression data set, ES Enrichment Score, NES Normalized Enrichment Score, NOM p-val Nominal P value, FDR q-val False Discovery Rate q value, FWER p-val Familywise-Error Rate q value, RANK AT MAX Rank at maximum enrichment score
Fig. 1Up- and down-regulated Enrichment Plots for a priori gene sets AD, psychiatric disorders, immune function, and cancer (Panels a–e). Venn diagram illustrating the overlap between the gene sets depicted in a–e